

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

Pursuant to the rules of the National Association of Financial Market Institutional Investors and the Shanghai Stock Exchange, Sinopharm Group Co. Ltd. (the “**Company**”) is required to publish the quarterly financial information of the Company and its subsidiaries (the “**Group**”) which consists of consolidated balance sheet, consolidated income statement and consolidated cash flow statement of the Group, and to publish the quarterly financial information of the Company which consists of balance sheet, income statement and cash flow statement of the Company.

This announcement is made pursuant to Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The board of directors of the Company is pleased to announce the unaudited financial information of the Group and of the Company for the nine months ended 30 September 2020 prepared in accordance with the PRC GAAP.

**CONSOLIDATED FINANCIAL INFORMATION OF THE GROUP FOR THE NINE MONTHS
ENDED 30 SEPTEMBER 2020**

Consolidated Balance Sheet of the Group as at 30 September 2020

(All amounts in RMB unless otherwise stated)

Items	As at 30 September 2020	As at 31 December 2019
Current assets:		
Cash at bank and on hand	39,449,334,736.32	49,845,600,097.60
Financial assets held for trading	39,165,070.00	155,890.00
Notes receivables	2,866,290,723.08	4,141,107,071.87
Accounts receivables	167,001,096,438.35	109,511,796,304.49
Accounts receivable financing	6,941,774,234.10	8,614,013,874.10
Advances to suppliers	8,839,373,542.10	8,704,573,680.53
Other receivables	5,565,360,799.79	5,048,132,261.34
Inventories	48,748,866,769.97	42,165,644,727.01
Contract assets	503,977,995.83	353,688,049.31
Current portion of non-current assets	70,490,374.61	151,088,229.03
Other current assets	645,995,990.65	1,033,115,028.21
Total current assets	280,671,726,674.80	229,568,915,213.49
Non-current assets:		
Long-term receivables	2,654,082,237.98	2,435,198,990.36
Long-term equity investments	7,493,865,034.19	7,052,380,866.25
Equity investments designated at fair value through other comprehensive income	55,610,548.77	38,284,404.72
Other non-current financial assets	679,943,279.19	729,892,288.09
Investment properties	1,064,850,439.54	1,122,841,879.38
Fixed assets	10,375,950,082.87	8,516,975,001.76
Construction in progress	574,027,861.29	2,310,198,391.06
Right-of-use assets	5,032,409,074.03	4,559,087,637.54
Intangible assets	4,805,152,634.40	4,626,092,448.01
Development costs	80,947,132.13	66,344,878.46
Goodwill	7,245,049,055.53	5,615,417,062.34
Long-term prepaid expenses	1,087,849,795.77	964,576,767.99
Deferred tax assets	1,435,498,321.82	1,349,010,469.17
Other non-current assets	942,931,282.59	782,637,256.42
Total non-current assets	43,528,166,780.10	40,168,938,341.55
Total assets	324,199,893,454.90	269,737,853,555.04

Consolidated Balance Sheet of the Group as at 30 September 2020 (continued)

(All amounts in RMB unless otherwise stated)

Items	As at 30 September 2020	As at 31 December 2019
Current liabilities:		
Short-term borrowings	55,757,797,504.71	29,050,807,578.16
Notes payables	27,105,781,055.92	29,321,645,497.63
Accounts payables	88,155,857,406.79	71,012,121,615.13
Contract liabilities	8,117,503,127.63	5,127,061,253.88
Employee benefits payable	1,414,353,142.14	1,792,563,851.99
Taxes payable	2,228,460,494.28	2,276,467,873.35
Other payables	21,976,828,818.81	24,905,606,324.62
Current portion of non-current liabilities	3,151,973,339.53	2,697,319,365.71
Other current liabilities	11,776,113,542.41	12,197,035,966.02
Total current liabilities	219,684,668,432.22	178,380,629,326.49
Non-current liabilities:		
Long-term borrowings	872,851,019.88	402,057,166.68
Bonds payables	9,992,011,131.63	7,912,143,541.65
Lease liabilities	3,497,530,414.57	3,097,484,984.69
Long-term payables	552,713,957.96	521,511,269.06
Long-term employee benefits payable	84,514,642.83	94,876,599.89
Provisions	83,777,417.09	35,578,085.95
Deferred income	392,887,875.62	369,843,847.60
Deferred tax liabilities	1,086,201,328.41	1,099,108,211.74
Other non-current liabilities	1,651,527,204.09	687,640,053.34
Total non-current liabilities	18,214,014,992.08	14,220,243,760.60
Total liabilities	237,898,683,424.30	192,600,873,087.09

Consolidated Balance Sheet of the Group as at 30 September 2020 (continued)*(All amounts in RMB unless otherwise stated)*

Items	As at 30 September 2020	As at 31 December 2019
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	3,120,656,191.00	2,971,656,191.00
Capital surplus	20,447,389,110.99	17,091,420,660.48
Less: treasury shares held for share incentive scheme	3,838,296.96	60,212,234.99
Other comprehensive income	1,913,383.56	(7,130,414.48)
Specific reserve	899,298.02	980,186.71
Surplus reserve	1,275,386,325.98	1,275,386,325.98
Undistributed profits	29,372,017,587.60	26,285,934,790.97
Total owners' equity (or shareholders' equity)		
attributable to equity holders of the parent	54,214,423,600.19	47,558,035,505.67
Minority interest	32,086,786,430.41	29,578,944,962.28
Total owners' equity (or shareholders' equity)	86,301,210,030.60	77,136,980,467.95
Total liabilities and owners' equity (or shareholders' equity):	324,199,893,454.90	269,737,853,555.04

Consolidated Income Statement of the Group for the Nine Months Ended 30 September 2020

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2020	For the nine months ended 30 September 2019
1. Total operating revenue	327,609,891,859.96	312,688,146,247.71
Including: Operating revenue	327,609,891,859.96	312,688,146,247.71
2. Total operating cost	315,917,992,936.21	301,831,191,549.80
Including: Operating cost	298,850,115,124.76	285,463,843,093.20
Taxes and surcharges	771,504,318.07	688,495,855.06
Selling and distribution expenses	9,851,291,134.75	8,937,506,759.67
General and administrative expenses	4,448,805,757.78	4,379,505,398.67
Research and development expenses	97,243,306.87	96,783,993.67
Financial expenses	1,899,033,293.98	2,265,056,449.53
Add: Other gains (loss shall be stated as “-”)	415,765,009.78	231,162,384.32
Investment income (loss shall be stated as “-”)	(32,254,786.90)	(507,525,526.64)
Profit arising from changes in fair value (loss shall be stated as “-”)	9,180.00	3,639,841.58
Credit impairment losses (loss shall be stated as “-”)	(1,016,345,884.33)	(660,886,641.60)
Asset impairment losses (loss shall be stated as “-”)	(325,449,269.38)	(112,742,997.87)
Gains on disposal of assets (loss shall be stated as “-”)	(6,000,007.00)	2,984,655.14
3. Operating profit (loss shall be stated as “-”)	10,727,623,165.92	9,813,586,412.84
Add: Non-operating income	91,017,355.58	52,200,009.12
Less: Non-operating expenses	89,187,196.77	47,930,450.10
4. Total profit (total loss shall be stated as “-”)	10,729,453,324.73	9,817,855,971.86
Less: Income tax expenses	2,437,539,397.04	2,207,405,668.79
5. Net profit (net loss shall be stated as “-”)	8,291,913,927.69	7,610,450,303.07
Classification according to the continuity of operation		
Net profit from continuing operations	8,291,913,927.69	7,610,450,303.07
Net profit from discontinued operations	-	-
Attributable to:		
Net profit attributable to equity holders of the parent	4,958,476,511.23	4,595,243,248.85
Net profit attributable to minority interest	3,333,437,416.46	3,015,207,054.22
6. Other comprehensive income/(loss), net of tax	7,044,704.51	(2,621,457.62)
Net other comprehensive income/(loss) attributable to equity holders of the parent	9,043,798.04	(3,925,199.25)
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods	4,846,188.02	800,189.24

**Consolidated Income Statement of the Group for the Nine Months Ended 30 September 2020
(continued)**

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2020	For the nine months ended 30 September 2019
Change in the remeasurements of post-employment benefit obligations	(2,104,527.21)	(677,904.41)
Change in the fair value of other equity instrument investments	6,950,715.23	1,478,093.65
<i>Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods</i>	4,197,610.02	(4,725,388.49)
Other comprehensive income using the equity method that may be reclassified to profit or loss	1,047,168.05	391,268.17
Exchange differences on translation of foreign operations	3,150,441.97	(5,116,656.66)
Net profit of other comprehensive (loss)/income attributable to minority interest	(1,999,093.53)	1,303,741.63
7. Total comprehensive income	8,298,958,632.20	7,607,828,845.45
Total comprehensive income attributable to equity holders of the parent	4,967,520,309.27	4,591,318,049.60
Total comprehensive income attributable to minority interest	3,331,438,322.93	3,016,510,795.86
8. Earnings per share:		
Basic earnings per share	1.66	1.55
Diluted earnings per share	1.66	1.55

Consolidated Cash Flow Statement of the Group for the Nine Months Ended 30 September 2020

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2020	For the nine months ended 30 September 2019
1. Cash flows from operating activities:		
Cash received from sales of goods or rendering of services	327,322,843,785.76	320,172,856,309.92
Refund of taxes and surcharges	237,444,535.88	106,271,885.61
Cash received relating to other operating activities	6,918,019,394.24	3,919,445,223.01
Sub-total of cash inflows from operating activities	334,478,307,715.88	324,198,573,418.54
Cash paid for goods and services	336,278,592,558.15	317,434,587,320.64
Cash paid to and on behalf of employees	8,186,952,610.41	7,363,701,179.50
Payments of taxes and surcharges	7,990,257,042.28	7,537,649,455.23
Cash paid relating to other operating activities	8,289,820,870.19	7,427,531,547.52
Sub-total of cash outflows from operating activities	360,745,623,081.03	339,763,469,502.89
Net cash flows used in operating activities	(26,267,315,365.15)	(15,564,896,084.35)
2. Cash flows from investing activities:		
Cash received from disposal of investments	95,836,537.21	86,153,181.88
Cash received from returns on investments	175,064,866.84	213,150,827.76
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	23,245,775.76	100,962,150.17
Net cash received from disposal of subsidiaries and other business units	-	(1,472,447.32)
Cash received relating to other investing activities	3,004,384,842.12	26,740,274.22
Sub-total of cash inflows from investing activities	3,298,532,021.93	425,533,986.71
Cash paid to acquire fixed assets, intangible assets and other long-term assets	1,122,792,325.33	1,406,688,040.11
Cash paid to acquire investments	105,185,222.66	231,259,837.91
Net cash paid to acquire subsidiaries and other business units	2,442,612,558.85	663,545,837.51
Cash paid relating to other investing activities	234,869,030.50	849,882,333.84
Sub-total of cash outflows from investing activities	3,905,459,137.34	3,151,376,049.37
Net cash flows used in investing activities	(606,927,115.41)	(2,725,842,062.66)

**Consolidated Cash Flow Statement of the Group for the Nine Months Ended 30 September 2020
(continued)**

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2020	For the nine months ended 30 September 2019
3. Cash flows from financing activities:		
Cash received from capital contributions	4,124,517,652.26	800,667,517.00
Cash received from borrowings	83,718,328,916.41	73,150,363,093.59
Cash received relating to other financing activities	<u>1,078,515,828.32</u>	<u>1,196,797,279.64</u>
Sub-total of cash inflows from financing activities	<u>88,921,362,396.99</u>	<u>75,147,827,890.23</u>
Cash repayments of borrowings	57,360,244,842.48	62,689,632,933.62
Cash payments for interest expenses and distribution of dividends or profits	6,120,708,729.04	6,076,968,396.63
Cash payments relating to other financing activities	<u>6,001,587,170.48</u>	<u>1,372,795,288.82</u>
Sub-total of cash outflows from financing activities	<u>69,482,540,742.00</u>	<u>70,139,396,619.07</u>
Net cash flows from financing activities	<u>19,438,821,654.99</u>	<u>5,008,431,271.16</u>
4. Effect of foreign exchange rate changes on cash and cash equivalents	<u>43,540,306.41</u>	<u>5,985,777.11</u>
5. Net decrease in cash and cash equivalents	<u>(7,391,880,519.16)</u>	<u>(13,276,321,098.74)</u>
Add: Cash and cash equivalents at the beginning of the reporting period	39,191,967,392.67	40,298,985,123.85
6. Cash and cash equivalents at the end of the reporting period	<u>31,800,086,873.51</u>	<u>27,022,664,025.11</u>

FINANCIAL INFORMATION OF THE COMPANY FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2020

Balance Sheet of the Company as at 30 September 2020

(All amounts in RMB unless otherwise stated)

Items	As at 30 September 2020	As at 31 December 2019
Current assets:		
Cash at bank and on hand	9,172,874,770.39	11,018,498,896.24
Notes receivables	-	-
Accounts receivables	3,642,501,899.63	2,514,809,679.20
Accounts receivable financing	67,629,651.40	74,347,958.23
Advances to suppliers	51,513,663.43	43,361,214.89
Other receivables	27,987,078,009.42	24,772,581,444.26
Inventories	797,777,220.24	766,788,024.90
Other current assets	1,294,910.22	135,469,732.22
Total current assets	41,720,670,124.73	39,325,856,949.94
Non-current assets:		
Long-term equity investments	31,447,763,709.16	31,748,693,232.06
Other non-current financial assets	570,151,697.24	593,518,796.14
Investment properties	817,831,487.45	23,690,889.21
Fixed assets	1,121,253,086.28	49,839,114.64
Construction in progress	42,318,981.50	1,910,019,590.12
Intangible assets	54,081,374.70	68,844,029.88
Long-term prepaid expenses	48,307,673.35	6,057,691.50
Deferred tax assets	38,134,469.40	111,401,229.14
Other non-current assets	89,228,771.26	89,052,122.88
Total non-current assets	34,229,071,250.34	34,601,116,695.57
Total assets	75,949,741,375.07	73,926,973,645.51

Balance Sheet of the Company as at 30 September 2020 (continued)*(All amounts in RMB unless otherwise stated)*

Items	As at 30 September 2020	As at 31 December 2019
Current liabilities:		
Short-term borrowings	1,651,208,333.33	-
Notes payables	78,883,376.23	727,973,777.18
Accounts payables	2,293,047,645.50	1,917,988,737.29
Contract liabilities	9,411,358.74	3,201,678.21
Employee benefits payable	36,215,729.24	96,889,909.22
Taxes payable	13,382,133.51	10,807,551.37
Other payables	16,843,797,509.96	22,571,311,647.10
Current portion of non-current liabilities	1,729,215,814.85	998,514,758.83
Other current liabilities	<u>11,691,463,276.33</u>	<u>11,677,806,654.20</u>
Total current liabilities	<u>34,346,625,177.69</u>	<u>38,004,494,713.40</u>
Non-current liabilities:		
Bonds payables	9,992,011,131.63	7,912,143,541.65
Deferred income	117,012.00	122,351.43
Deferred Tax Liabilities	22,796,546.27	22,796,546.27
Other non-current liabilities	<u>1,173,220,750.23</u>	<u>864,072,542.23</u>
Total non-current liabilities	<u>11,188,145,440.13</u>	<u>8,799,134,981.58</u>
Total liabilities	<u>45,534,770,617.82</u>	<u>46,803,629,694.98</u>

Balance Sheet of the Company as at 30 September 2020 (continued)*(All amounts in RMB unless otherwise stated)*

Items	As at 30 September 2020	As at 31 December 2019
Owners' equity (or shareholders' equity):		
Paid-in capital (or share capital)	3,120,656,191.00	2,971,656,191.00
Capital surplus	24,431,769,237.04	21,022,725,298.26
Less: treasury shares held for share incentive scheme	3,838,296.96	60,212,234.99
Other comprehensive income	5,786,963.39	4,855,489.46
Surplus reserve	1,276,053,477.70	1,276,053,477.70
Undistributed profits	<u>1,584,543,185.08</u>	<u>1,908,265,729.10</u>
Total owners' equity (or shareholders' equity)	<u>30,414,970,757.25</u>	<u>27,123,343,950.53</u>
Total liabilities and owners' equity (or shareholders' equity)	<u>75,949,741,375.07</u>	<u>73,926,973,645.51</u>

Income Statement of the Company for the Nine Months Ended 30 September 2020

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2020	For the nine months ended 30 September 2019
1. Total operating revenue	11,285,163,232.98	12,182,565,592.96
Including: Operating revenue	11,285,163,232.98	12,182,565,592.96
2. Total operating cost	11,056,524,322.76	12,238,084,323.72
Including: Operating cost	10,670,552,495.68	11,559,271,920.07
Taxes and surcharges	12,021,837.86	21,129,024.75
Selling and distribution expenses	151,748,585.99	187,318,166.03
General and administrative expenses	205,668,153.81	287,441,371.64
Research and development expenses	-	-
Financial expenses	16,533,249.42	182,923,841.23
Add: Other gains (loss shall be stated as “-”)	35,988,192.99	22,749,391.85
Investment income (loss shall be stated as “-”)	1,375,854,746.46	1,191,994,274.29
Profit arising from changes in fair value (loss shall be stated as “-”)	-	3,779,561.58
Credit impairment losses (loss shall be stated as “-”)	(14,596,564.80)	(10,425,755.06)
Asset impairment losses (loss shall be stated as “-”)	(857,422.45)	12,644,215.42
Gains on disposal of assets (loss shall be stated as “-”)	-	-
3. Operating profit (loss shall be stated as “-”)	1,625,027,862.42	1,165,222,957.32
Add: Non-operating income	1,206,351.76	203,547.09
Less: Non-operating expenses	3,116,151.14	145,064.45
4. Total profit (total loss shall be stated as “-”)	1,623,118,063.04	1,165,281,439.96
Less: Income tax expenses	74,446,892.46	3,950,365.49
5. Net profit (net loss shall be stated as “-”)	1,548,671,170.58	1,161,331,074.47
Classification according to the continuity of operation		
Net profit from continuing operations	1,548,671,170.58	1,161,331,074.47
Net profit from discontinued operations	-	-

Income Statement of the Company for the Nine Months Ended 30 September 2020 (continued)*(All amounts in RMB unless otherwise stated)*

Items	For the nine months ended 30 September 2020	For the nine months ended 30 September 2019
6. Other comprehensive income/(loss), net of tax	931,473.93	(775,916.42)
<i>Other comprehensive income/(loss) that will not be reclassified to profit or loss in subsequent periods</i>	-	-
<i>Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods</i>	931,473.93	(775,916.42)
Other comprehensive income/(loss) using the equity method that may be reclassified to profit or loss	931,473.93	(775,916.42)
7. Total comprehensive income	<u>1,549,602,644.51</u>	<u>1,160,555,158.05</u>

Cash Flow Statement of the Company for the Nine Months Ended 30 September 2020

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2020	For the nine months ended 30 September 2019
1. Cash flows from operating activities:		
Cash received from sales of goods or rendering of services	11,463,114,256.34	12,636,019,211.46
Refund of taxes and surcharges	-	-
Cash received relating to other operating activities	1,923,406,821.39	619,676,223.88
Sub-total of cash inflows from operating activities	13,386,521,077.73	13,255,695,435.34
Cash paid for goods and services	12,177,068,825.75	13,141,199,405.07
Cash paid to and on behalf of employees	193,718,755.40	212,571,500.38
Payments of taxes and surcharges	56,872,903.68	155,689,746.86
Cash paid relating to other operating activities	1,782,054,764.31	688,552,642.90
Sub-total of cash outflows from operating activities	14,209,715,249.14	14,198,013,295.21
Net cash flows used in operating activities	(823,194,171.41)	(942,317,859.87)
2. Cash flows from investing activities:		
Cash received from disposal of investments	554,641,752.02	65,453,503.88
Cash received from returns on investments	1,275,228,327.98	1,019,279,987.76
Net cash received from disposals of fixed assets, intangible assets and other long-term assets	342,833.47	-
Net cash received from disposal of subsidiaries and other business units	198,243,055.93	(1,472,447.32)
Cash received relating to other investing activities	4,874,489,086.95	2,121,953,511.88
Sub-total of cash inflows from investing activities	6,902,945,056.35	3,205,214,556.20
Cash paid to acquire fixed assets, intangible assets and other long-term assets	36,240,462.90	41,342,820.51
Cash paid to acquire investments	363,847,331.56	693,162,622.40
Cash paid relating to other investing activities	6,905,962,968.99	8,069,140,963.44
Sub-total of cash outflows from investing activities	7,306,050,763.45	8,803,646,406.35
Net cash flows used in investing activities	(403,105,707.10)	(5,598,431,850.15)

Cash Flow Statement of the Company for the Nine Months Ended 30 September 2020
(continued)

(All amounts in RMB unless otherwise stated)

Items	For the nine months ended 30 September 2020	For the nine months ended 30 September 2019
3. Cash flows from financing activities:		
Cash received from capital contributions	3,567,382,957.30	-
Cash received from borrowings	19,828,964,466.67	28,773,134,783.19
Cash received relating to other financing activities	213,051,221,382.66	210,692,714,773.14
Sub-total of cash inflows from financing activities	236,447,568,806.63	239,465,849,556.33
Cash repayments of borrowings	15,500,000,000.00	22,665,355,483.19
Cash payments for interest expenses and distribution of dividends or profits	2,391,124,768.17	2,279,444,693.88
Cash payments relating to other financing activities	219,224,164,579.80	216,950,174,850.13
Sub-total of cash outflows from financing activities	237,115,289,347.97	241,894,975,027.20
Net cash flows used in financing activities	(667,720,541.34)	(2,429,125,470.87)
4. Effect of foreign exchange rate changes on cash and cash equivalents	48,396,294.00	1,035,214.53
5. Net decrease in cash and cash equivalents	(1,845,624,125.85)	(8,968,839,966.36)
Add: Cash and cash equivalents at the beginning of the reporting period	11,018,498,896.24	14,688,606,790.90
6. Cash and cash equivalents at the end of the reporting period	9,172,874,770.39	5,719,766,824.54

By order of the Board
Sinopharm Group Co. Ltd.
Li Zhiming
Chairman

Shanghai, the PRC
22 October 2020

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

* The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd."